Source: Annual Congress 2002 - Early diagnosis and prevention in children with atopy
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Migoya, J. Zhao, J. D. Rogers, A. Hartford, J. van Adelsberg, C. Bonfiglio, B. Knorr, P. J. Deutsch (Rahway, West Point, ; Rahway, United States Of America). Dose selection and pharmacokinetics of montelukast (sprinkles) in >=6 month to <2 year old asthmatic patients. Eur Respir J 2002; 20: Suppl. 38, 3268

Member's Comments

No comment yet.

Related content which might interest you: Montelukast is safe and well tolerated in >=6 month to <2 year old patients Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002 Low dose inhaled fluticasone propionate compared with montelukast in children 6-12 years old Source: Eur Respir J 2003; 22: Suppl. 45, 535s Year: 2003 The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002 The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005 Influence of an incentive spacer on adherence to prescribed treatment in 2-6 year old children over a 3 month period Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007 Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) Source: Annual Congress 2009 - New bronchodilators Year: 2009 Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008 Efficacy of montelukast in patients aged 2 to 5 years with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 377s Year: 2004 Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2-agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011 Efficacy, safety and tolerability of 3 day azithromycin (A) versus 10-day conventional treatment (CT) in the treatment of children with acute asthma exacerbation (AE) Source: Eur Respir J 2005; 26: Suppl. 49, 135s Year: 2005 A comparison of nebulized budesonide, intramuscular and oral dexamethasone in the treatment of croup among children aged 6-36 months Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003 Formoterol in acute asthma in children 6-14 years old Source: Eur Respir J 2003; 22: Suppl. 45, 133s Year: 2003 Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013 Montelukast vs. fluticasone in patients aged 6 to 14 with mild persistent asthma: the MOSAIC study Source: Eur Respir J 2004; 24: Suppl. 48, 377s Year: 2004 A randomised, 4-way crossover study to examine the lung pharmacodynamic effects of single inhaled doses of tiotropium (18 μg), salmeterol (50 μg), tiotropium (18 μg) and salmeterol (50 μg) and placebo using whole body plethysmography in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010 Single dose of of tiotropium bromide (18 mcg) produces a similar bronchodilator response as two doses of formoterol fumarate (12 mcg ) over 24 hours in subjects with moderate-to-severe asthma Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Comparison of ciclesonide once daily (80 μg/d, 160 μg/d) and fluticasone propionate twice daily (176 μg/d) in the treatment of children with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 457s Year: 2007 Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 "Stepping down" in mild-to-moderate asthmatic children, being well controlled while receiving low doses of inhaled corticosteroids (ICS): nedocromil sodium (NS) vs. fluticasone propionate (FP) 100 mcg/day given either twice Source: Eur Respir J 2006; 28: Suppl. 50, 713s Year: 2006